Physician profile
Peter Scivoletti
NPI 1437182581
$4,998.99
in general payments reported to CMS, 2019-2025
9 companies · $250 in 2025
The $250 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,341 · 2020: $1,057 · 2021: $950 · 2022: $846 · 2023: $430 · 2024: $125 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $805.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $805.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,840.37 | 2021-2025 | Ubrelvy, Qulipta |
| Astrazeneca Pharmaceuticals LP | $871.73 | 2019-2022 | |
| Allergan, INC. | $629.58 | 2019-2020 | |
| Novo Nordisk INC | $594.01 | 2019-2025 | Wegovy |
| Janssen Pharmaceuticals, INC | $486.52 | 2019-2020 | |
| Amarin Pharma, INC. | $279.09 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $115.36 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $102.85 | 2019 | |
| Glaxosmithkline, LLC. | $79.48 | 2023 | Arexvy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Scivoletti listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.